MRI distinguishes brain lesions, possibly supplementing existing diagnostic algorithms
MR images can reveal perivenous multiple sclerosis (MS) lesions, and distinguish them from microangiopathic lesions, according to a study published in the Multiple Sclerosis Journal.
Researchers from the United Kingdom undertook a small (40 patients) study to determine if MRI could differentiate MS from microangiopathic brain lesions. Twenty patients (10 with MS and 10 patients with microangiopathic white matter lesions) underwent 3T T2*-weighted MRI. Their scans were anonymized, blind to clinical data, and simple diagnostic rules were devised. Following this, another 13 patients with MS and seven with microangiopathic lesions were scanned as the validation cohort, and the same rules were applied.[[{"type":"media","view_mode":"media_crop","fid":"45682","attributes":{"alt":"Nikos Evangelou, MD","class":"media-image media-image-right","id":"media_crop_3453240569737","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"5246","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"height: 135px; width: 180px; border-width: 0px; border-style: solid; margin: 1px; float: right;","title":"Nikos Evangelou, MD","typeof":"foaf:Image"}}]]
The results showed that the MS patients in the test (first) cohort had visible central lines in more than 45% of the brain lesions, while the rest had visible central lines in fewer than 45% of the lesions. The patients in the validation cohort were then all correctly categorized by applying the diagnostic rules.
“We already knew that large research MRI scanners could detect the proportion of lesions with a vein in the brain's white matter, but these scanners are not clinically available,” lead author Nikos Evangelou, MD, said in a release. “So we wanted to find out whether a single brain scan in an NHS hospital scanner could also be effective in distinguishing between patients known to have MS and patients known to have non-MS brain lesions. We are excited to reveal that our results show that clinical application of this technique could supplement existing diagnostic methods for MS."
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.